Annovis Bio Files 8-K
Ticker: ANVS · Form: 8-K · Filed: Jul 2, 2024 · CIK: 1477845
| Field | Detail |
|---|---|
| Company | Annovis Bio, Inc. (ANVS) |
| Form Type | 8-K |
| Filed Date | Jul 2, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, SEC-filing, reporting
TL;DR
Annovis Bio filed a standard 8-K, no major news.
AI Summary
Annovis Bio, Inc. filed an 8-K on July 2, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or new material events beyond the standard reporting requirements.
Why It Matters
This 8-K filing indicates routine corporate reporting by Annovis Bio, Inc. to the SEC, without disclosing new material information.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report and does not contain any new material information that would immediately impact the company's risk profile.
Key Players & Entities
- Annovis Bio, Inc. (company) — Registrant
- QR Pharma, Inc. (company) — Former company name
FAQ
What is the purpose of this 8-K filing?
This 8-K filing serves as a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting a Regulation FD Disclosure and Financial Statements and Exhibits.
What is the exact name of the registrant?
The exact name of the registrant is Annovis Bio, Inc.
In which state was Annovis Bio, Inc. incorporated?
Annovis Bio, Inc. was incorporated in Delaware.
What is the principal executive office address for Annovis Bio, Inc.?
The address of the Principal Executive Offices is 101 Lindenwood Drive, Suite 225, Malvern, PA 19355.
What was the former name of Annovis Bio, Inc. and when did the name change occur?
The former company name was QR Pharma, Inc., and the date of the name change was December 2, 2009.
Filing Stats: 480 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2024-07-02 08:14:02
Key Financial Figures
- $0.0001 — h registered Common Stock, par value $0.0001 per share ANVS New York Stock Exchang
Filing Documents
- tm2418712d1_8k.htm (8-K) — 27KB
- tm2418712d1_ex99-1.htm (EX-99.1) — 29KB
- tm2418712d1_ex99-1img001.jpg (GRAPHIC) — 17KB
- tm2418712d1_ex99-1img002.jpg (GRAPHIC) — 23KB
- tm2418712d1_ex99-1img003.jpg (GRAPHIC) — 27KB
- 0001104659-24-077093.txt ( ) — 327KB
- anvs-20240702.xsd (EX-101.SCH) — 3KB
- anvs-20240702_lab.xml (EX-101.LAB) — 33KB
- anvs-20240702_pre.xml (EX-101.PRE) — 22KB
- tm2418712d1_8k_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure On July 2, 2024, Annovis Bio, Inc. ("The Company") issued a press release announcing new data from its Phase III Parkinson's study. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The Company plans to hold a webcast at 4:30 PM ET, after market close o n July 2, 2024, to discuss the study findings in detail. A registration link can be found in the copy of this press release posted on the Investors section of our website. Item 9.01 Financial Statements and Exhibits. The following exhibits are being furnished herewith: (d) Exhibits. Exhibit No. Description 99.1 Press Release Dated July 2, 2024 104 Cover Page Interactive Data File
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ANNOVIS BIO, INC. Date: July 2, 2024 By: /s/ Maria Maccecchini Name: Maria Maccecchini Title: President and Chief Executive Officer